Results 241 to 250 of about 36,119 (263)

Denosumab

Reactions Weekly, 2018
  +5 more sources

Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone

Nature Reviews Rheumatology, 2023
Serge Ferrari
exaly  

Denosumab

Terapia, 2014
  +5 more sources

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Lancet, The, 2011
Janet E Brown, Lawrence I Karsh, Piotr Milecki   +2 more
exaly  

Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial

Lancet Oncology, The, 2020
Robert Coleman, Frcp, Dianne M Finkelstein, Carlos Henrique Barrios   +2 more
exaly  

Denosumab in patients with cancer—a surgical strike against the osteoclast

Nature Reviews Clinical Oncology, 2012
Janet E Brown
exaly  

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

Lancet Diabetes and Endocrinology,the, 2017
Henry Bone, Jacques P Brown, Roland D Chapurlat   +2 more
exaly  

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

Lancet, The, 2012
Fred Saad, Bertrand Tombal, Lawrence I Karsh   +2 more
exaly  

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial

Lancet, The, 2015
Benjamin Z Leder, Hang Lee, Sherri-Ann M Burnett-Bowie   +2 more
exaly  

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

Lancet, The, 2013
Hang Lee, Sherri-Ann M Burnett-Bowie, Benjamin Z Leder   +2 more
exaly